Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	IgG receptor activity	FCGR2C FCGR2A FCGR2B	1.18e-05	7	141	3	GO:0019770
GeneOntologyMolecularFunction	IgG binding	FCGR2C FCGR2A FCGR2B	5.46e-05	11	141	3	GO:0019864
GeneOntologyMolecularFunction	immunoglobulin receptor activity	FCGR2C FCGR2A FCGR2B	1.19e-04	14	141	3	GO:0019763
GeneOntologyMolecularFunction	low-affinity IgG receptor activity	FCGR2A FCGR2B	2.94e-04	4	141	2	GO:0019772
GeneOntologyBiologicalProcess	negative regulation of hypersensitivity	SPN FCGR2A FCGR2B	1.17e-06	4	138	3	GO:0002884
GeneOntologyBiologicalProcess	hypersensitivity	SPN FCGR2C FCGR2A FCGR2B	2.18e-05	25	138	4	GO:0002524
GeneOntologyBiologicalProcess	negative regulation of acute inflammatory response to antigenic stimulus	SPN FCGR2A FCGR2B	2.39e-05	9	138	3	GO:0002865
GeneOntologyBiologicalProcess	negative regulation of type I hypersensitivity	FCGR2A FCGR2B	4.44e-05	2	138	2	GO:0001811
GeneOntologyBiologicalProcess	antibody-dependent cellular cytotoxicity	FCGR2C FCGR2A FCGR2B	7.98e-05	13	138	3	GO:0001788
GeneOntologyBiologicalProcess	animal organ morphogenesis	SPRY2 IFT140 HNF1A INTU ERBB4 PLOD3 KAT6A DVL2 DUOX2 ZMIZ1 SIK3 TIPARP LHX1 HHIP NFIC TP63 NFKB1 LRP2 MYO15A EMX2 UTY	1.07e-04	1269	138	21	GO:0009887
GeneOntologyBiologicalProcess	type IIa hypersensitivity	FCGR2C FCGR2A FCGR2B	1.26e-04	15	138	3	GO:0001794
GeneOntologyBiologicalProcess	type II hypersensitivity	FCGR2C FCGR2A FCGR2B	1.26e-04	15	138	3	GO:0002445
GeneOntologyCellularComponent	axonal growth cone	MAPK8IP1 CLASP2 LRP2 COBL TRAK2	1.37e-05	45	143	5	GO:0044295
MousePheno	umbilical hernia	NBEA TP63 NPRL3 LRP2	2.04e-06	12	115	4	MP:0010146
MousePheno	abnormal palate morphology	BNC2 SPRY2 IFT140 PLOD3 KAT6A NBEA TIPARP TP63 KCNJ13 NPRL3 LRP2 GAB1	1.30e-05	321	115	12	MP:0003755
MousePheno	cleft palate	BNC2 SPRY2 IFT140 PLOD3 KAT6A NBEA TP63 KCNJ13 NPRL3 LRP2 GAB1	2.58e-05	289	115	11	MP:0000111
MousePheno	oral cleft	BNC2 SPRY2 IFT140 PLOD3 KAT6A NBEA TP63 KCNJ13 NPRL3 LRP2 GAB1	2.75e-05	291	115	11	MP:0021164
MousePheno	abnormal uterine cervix epithelium morphology	BRCA1 TP63	6.71e-05	2	115	2	MP:0001137
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	FOXO1 MAGI1 GAPVD1 ERBB4 HIVEP1 TRIO TBC1D5 SAMD4B CLASP2 PLEKHG2 SIK3 PRAG1 LYST CEP350 PRRC2C STARD9 COBL GAB1 DMTN	3.71e-09	861	145	19	36931259
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	TRMT9B PITPNM2 MAGI1 INTU TRIO RASA3 NLGN4Y KIZ TBC1D5 SAMD4B KAT6A CLASP2 POMT1 ZMIZ1 UBN2 PTPRG TESMIN ZNF827 NFIC COBL ZNF839 NFAT5 ZMYM4 FAM149A	1.32e-08	1489	145	24	28611215
Pubmed	Functional Fcgamma receptor polymorphisms are associated with human allergy.	FCGR2C FCGR2A FCGR2B	7.10e-08	3	145	3	24586589
Pubmed	Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression.	FCGR2C FCGR2A FCGR2B	7.10e-08	3	145	3	26133275
Pubmed	Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traits.	MAGI1 CLSTN2 NFKB1 EMX2 NFAT5	2.54e-07	33	145	5	24204828
Pubmed	Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B.	FCGR2C FCGR2A FCGR2B	7.05e-07	5	145	3	19309690
Pubmed	Siglec-G Deficiency Leads to Autoimmunity in Aging C57BL/6 Mice.	FCGR2A FCGR2B SIGLEC10	7.05e-07	5	145	3	25987743
Pubmed	SNPs of Fc-gamma receptor genes and chronic periodontitis.	FCGR2C FCGR2A FCGR2B	7.05e-07	5	145	3	20439936
Pubmed	Copy number, linkage disequilibrium and disease association in the FCGR locus.	FCGR2C FCGR2A FCGR2B	7.05e-07	5	145	3	20508037
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	PITPNM2 SPRY2 PLOD3 SEMA7A TRIO RASA3 KAT6A AOC2 CLASP2 SMG5 PRAG1 BIRC6 LYST ABCA7 ZNF827 NPRL3 COBL ZNF839	8.86e-07	1105	145	18	35748872
Pubmed	Genomic analysis of mouse retinal development.	PITPNM2 RASA3 SCYL3 DVL2 MAU2 UBN2 LHX2 MPP4 NFIC CIAO1 TONSL LPIN2 CCAR2 TRAK2 MTUS2 ZMYM4 GABBR1	1.11e-06	1006	145	17	15226823
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	GAPVD1 TRIO CLASP2 CEP350 MISP COBL TRAK2 GAB1	2.93e-06	209	145	8	36779422
Pubmed	Co-clustering of Fcgamma and B cell receptors induces dephosphorylation of the Grb2-associated binder 1 docking protein.	FCGR2A FCGR2B GAB1	3.91e-06	8	145	3	11453982
Pubmed	Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.	PITPNM2 SEMA7A TRIO DSG1 CLASP2 SMG5 FRY PRRC2C A2ML1 NFAT5 MTUS2	5.38e-06	475	145	11	31040226
Pubmed	A human MAP kinase interactome.	CCDC14 MAGI1 IFT140 HIVEP1 MUC12 SIK3 CEP350 COBL ZNF839 TNS1 GAB1	6.68e-06	486	145	11	20936779
Pubmed	Tagging genes with cassette-exchange sites.	BNC2 CLASP2 SMG5 BIRC6 WAC PRRC2C TNS1 ZMYM4 DMTN	1.23e-05	335	145	9	15741177
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	ERBB4 SPATA31E1 TBC1D5 MAU2 TEX14 TP63 BUB1 TONSL PLEKHO1 GAB1	1.41e-05	430	145	10	35044719
Pubmed	Novel Mechanism of Foxo1 Phosphorylation in Glucagon Signaling in Control of Glucose Homeostasis.	FOXO1 LEPR	1.73e-05	2	145	2	30201683
Pubmed	Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection.	FCGR2A FCGR2B	1.73e-05	2	145	2	23616574
Pubmed	Antigen-Specific IgG ameliorates allergic airway inflammation via Fcγ receptor IIB on dendritic cells.	FCGR2A FCGR2B	1.73e-05	2	145	2	21477339
Pubmed	Opposite regulation of type II and III receptors for immunoglobulin G in mouse glomerular mesangial cells and in the induction of anti-glomerular basement membrane (GBM) nephritis.	FCGR2A FCGR2B	1.73e-05	2	145	2	11983693
Pubmed	Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition.	FCGR2A FCGR2B	1.73e-05	2	145	2	20083655
Pubmed	Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1.	ERBB4 BRCA1	1.73e-05	2	145	2	16914727
Pubmed	Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.	FCGR2A FCGR2B	1.73e-05	2	145	2	21357255
Pubmed	Association of FcγRIIB and FcγRIIA R131H gene polymorphisms with renal involvement in Egyptian systemic lupus erythematosus patients.	FCGR2A FCGR2B	1.73e-05	2	145	2	24366619
Pubmed	Differences in endocytosis mediated by FcγRIIA and FcγRIIB2.	FCGR2A FCGR2B	1.73e-05	2	145	2	21945020
Pubmed	FcγRIIb on liver sinusoidal endothelium clears small immune complexes.	FCGR2A FCGR2B	1.73e-05	2	145	2	23053513
Pubmed	Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease.	FCGR2A FCGR2B	1.73e-05	2	145	2	10704470
Pubmed	Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII.	FCGR2A FCGR2B	1.73e-05	2	145	2	10704418
Pubmed	Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-kappaB activity.	NFKB1 NFAT5	1.73e-05	2	145	2	20685965
Pubmed	Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1.	BRCA1 ZNF350	1.73e-05	2	145	2	11090615
Pubmed	Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.	FCGR2A FCGR2B	1.73e-05	2	145	2	23897982
Pubmed	CD32B, the human inhibitory Fc-gamma receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma.	FCGR2A FCGR2B	1.73e-05	2	145	2	16757681
Pubmed	Fc receptor beta chain deficiency exacerbates murine arthritis in the anti-type II collagen antibody-induced experimental model.	FCGR2A FCGR2B	1.73e-05	2	145	2	23053716
Pubmed	Fc gamma RIIB regulates nasal and oral tolerance: a role for dendritic cells.	FCGR2A FCGR2B	1.73e-05	2	145	2	15843524
Pubmed	Lupus nephritis progression in FcγRIIB-/-yaa mice is associated with early development of glomerular electron dense deposits and loss of renal DNase I in severe disease.	FCGR2A FCGR2B	1.73e-05	2	145	2	29190833
Pubmed	Comment on "The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility".	FCGR2A FCGR2B	1.73e-05	2	145	2	21969314
Pubmed	Lupus-Associated Immune Complexes Activate Human Neutrophils in an FcγRIIA-Dependent but TLR-Independent Response.	FCGR2A FCGR2B	1.73e-05	2	145	2	30610165
Pubmed	Fc receptors.	FCGR2A FCGR2B	1.73e-05	2	145	2	1910686
Pubmed	NF-κB is a critical mediator of BRCA1-induced chemoresistance.	BRCA1 NFKB1	1.73e-05	2	145	2	23435429
Pubmed	Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus.	FCGR2A FCGR2B	1.73e-05	2	145	2	10508186
Pubmed	A lupus-suppressor BALB/c locus restricts IgG2 autoantibodies without altering intrinsic B cell-tolerance mechanisms.	FCGR2A FCGR2B	1.73e-05	2	145	2	18322187
Pubmed	Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease.	FCGR2A FCGR2B	1.73e-05	2	145	2	17322382
Pubmed	Defective Fc gamma RII gene expression in macrophages of NOD mice: genetic linkage with up-regulation of IgG1 and IgG2b in serum.	FCGR2A FCGR2B	1.73e-05	2	145	2	8906852
Pubmed	CD16/32-specific biotinylated 2.4G2 single-chain Fv complexed with avidin-FITC enhances FITC-specific humoral immune response in vivo in a CD16-dependent manner.	FCGR2A FCGR2B	1.73e-05	2	145	2	19951957
Pubmed	Aberrant Forkhead box O1 function is associated with impaired hepatic metabolism.	FOXO1 LEPR	1.73e-05	2	145	2	16997836
Pubmed	FcγRIIB mediates the inhibitory effect of aggregated α-synuclein on microglial phagocytosis.	FCGR2A FCGR2B	1.73e-05	2	145	2	26342897
Pubmed	FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis.	FCGR2A FCGR2B	1.73e-05	2	145	2	14981111
Pubmed	Analysis of a wild mouse promoter variant reveals a novel role for FcγRIIb in the control of the germinal center and autoimmunity.	FCGR2A FCGR2B	1.73e-05	2	145	2	23109709
Pubmed	Augmentation of pulmonary host defense against Pseudomonas by FcgammaRIIA cDNA transfer to the respiratory epithelium.	FCGR2A FCGR2B	1.73e-05	2	145	2	10449433
Pubmed	Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis.	FCGR2A FCGR2B	1.73e-05	2	145	2	10981970
Pubmed	The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN.	FCGR2A FCGR2B	1.73e-05	2	145	2	23411782
Pubmed	The impact of genetic susceptibility to systemic lupus erythematosus on placental malaria in mice.	FCGR2A FCGR2B	1.73e-05	2	145	2	23675429
Pubmed	Structure and expression of human IgG FcRII(CD32). Functional heterogeneity is encoded by the alternatively spliced products of multiple genes.	FCGR2A FCGR2B	1.73e-05	2	145	2	2529342
Pubmed	Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG.	FCGR2A FCGR2B	1.73e-05	2	145	2	10330436
Pubmed	Polymorphism of Fc receptor on murine B cells is Igh-linked.	FCGR2A FCGR2B	1.73e-05	2	145	2	3159826
Pubmed	The pre-B cell receptor signaling for apoptosis is negatively regulated by Fc gamma RIIB.	FCGR2A FCGR2B	1.73e-05	2	145	2	11777955
Pubmed	FcgammaRIIB regulates autoreactive primary antibody-forming cell, but not germinal center B cell, activity.	FCGR2A FCGR2B	1.73e-05	2	145	2	17202351
Pubmed	Immune complex enhances tolerogenecity of immature dendritic cells via FcγRIIb and promotes FcγRIIb-overexpressing dendritic cells to attenuate lupus.	FCGR2A FCGR2B	1.73e-05	2	145	2	21360699
Pubmed	The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.	FCGR2A FCGR2B	1.73e-05	2	145	2	27893416
Pubmed	Fc gamma receptor IIb modulates the molecular Grb2 interaction network in activated B cells.	FCGR2A FCGR2B	1.73e-05	2	145	2	21262349
Pubmed	Adenovirus-mediated Overexpression of FcγRIIB Attenuates Pulmonary Inflammation and Fibrosis.	FCGR2A FCGR2B	1.73e-05	2	145	2	36227848
Pubmed	Spatial raft coalescence represents an initial step in Fc gamma R signaling.	FCGR2A FCGR2B	1.73e-05	2	145	2	12077245
Pubmed	Ontogeny and distribution of the murine B cell Fc gamma RII.	FCGR2A FCGR2B	1.73e-05	2	145	2	1387140
Pubmed	Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis.	FCGR2A FCGR2B	1.73e-05	2	145	2	21746933
Pubmed	Prominent Indomethacin-Induced Enteropathy in Fcgriib Defi-cient lupus Mice: An Impact of Macrophage Responses and Immune Deposition in Gut.	FCGR2A FCGR2B	1.73e-05	2	145	2	33573095
Pubmed	The Complex Association of FcγRIIb With Autoimmune Susceptibility.	FCGR2A FCGR2B	1.73e-05	2	145	2	31681256
Pubmed	Important role for FcγRIIB on B lymphocytes for mucosal antigen-induced tolerance and Foxp3+ regulatory T cells.	FCGR2A FCGR2B	1.73e-05	2	145	2	24038083
Pubmed	Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.	FCGR2A FCGR2B	1.73e-05	2	145	2	22508937
Pubmed	Differential recruitment of activating and inhibitory Fc gamma RII during phagocytosis.	FCGR2A FCGR2B	1.73e-05	2	145	2	20154205
Pubmed	Alleles of the Ly-17 alloantigen define polymorphisms of the murine IgG Fc receptor.	FCGR2A FCGR2B	1.73e-05	2	145	2	3865190
Pubmed	TAp63 is a transcriptional target of NF-kappaB.	TP63 NFKB1	1.73e-05	2	145	2	20052674
Pubmed	An insulin-independent mechanism for transcriptional regulation of Foxo1 in type 2 diabetic mice.	FOXO1 LEPR	1.73e-05	2	145	2	34058194
Pubmed	Expression of Fc gamma RIII defines distinct subpopulations of fetal liver B cell and myeloid precursors.	FCGR2A FCGR2B	1.73e-05	2	145	2	7664793
Pubmed	Selective regulation of autoreactive B cells by FcgammaRIIB.	FCGR2A FCGR2B	1.73e-05	2	145	2	19327966
Pubmed	Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses.	FCGR2A FCGR2B	1.73e-05	2	145	2	12370366
Pubmed	FcgammaRIIa and FcgammaRIIIb polymorphisms were not associated with meningococcal disease in Western Norway.	FCGR2A FCGR2B	1.73e-05	2	145	2	12729187
Pubmed	Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors.	FCGR2A FCGR2B	1.73e-05	2	145	2	2946078
Pubmed	FcgRIII Deficiency and FcgRIIb Defeciency Promote Renal Injury in Diabetic Mice.	FCGR2A FCGR2B	1.73e-05	2	145	2	31534958
Pubmed	PFKP is transcriptionally repressed by BRCA1/ZBRK1 and predicts prognosis in breast cancer.	BRCA1 ZNF350	1.73e-05	2	145	2	32470015
Pubmed	ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.	BRCA1 TP63	1.73e-05	2	145	2	26704768
Pubmed	Identification of DBC1 as a transcriptional repressor for BRCA1.	BRCA1 CCAR2	1.73e-05	2	145	2	20160719
Pubmed	Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility.	FCGR2A FCGR2B	1.73e-05	2	145	2	10866109
Pubmed	FcgammaRIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro.	FCGR2A FCGR2B	1.73e-05	2	145	2	11698426
Pubmed	FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase.	FCGR2A FCGR2B	1.73e-05	2	145	2	16269657
Pubmed	The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility.	FCGR2A FCGR2B	1.73e-05	2	145	2	21724994
Pubmed	Human adipose-derived mesenchymal stem cells attenuate collagen antibody-induced autoimmune arthritis by inducing expression of FCGIIB receptors.	FCGR2A FCGR2B	1.73e-05	2	145	2	26210906
Pubmed	The Lupus-Associated Fcγ Receptor IIb-I232T Polymorphism Results in Impairment in the Negative Selection of Low-Affinity Germinal Center B Cells Via c-Abl in Mice.	FCGR2A FCGR2B	1.73e-05	2	145	2	29774664
Pubmed	Identification of the low affinity receptor for immunoglobulin E on mouse mast cells and macrophages as Fc gamma RII and Fc gamma RIII.	FCGR2A FCGR2B	1.73e-05	2	145	2	1386873
Pubmed	FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.	FCGR2A FCGR2B	1.73e-05	2	145	2	38147316
Pubmed	Inhibitory IgG Fc receptor promoter region polymorphism is a key genetic element for murine systemic lupus erythematosus.	FCGR2A FCGR2B	1.73e-05	2	145	2	19758787
Pubmed	Epidermal overexpression of transgenic ΔNp63 promotes type 2 immune and myeloid inflammatory responses and hyperplasia via NF-κB activation.	TP63 NFKB1	1.73e-05	2	145	2	24258200
Pubmed	Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria.	FCGR2A FCGR2B	1.73e-05	2	145	2	17435165
Pubmed	Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance.	FCGR2A FCGR2B	1.73e-05	2	145	2	28479335
Pubmed	Assignment of the gene coding for human FcRII (CD32) to bands q23q24 on chromosome 1.	FCGR2A FCGR2B	1.73e-05	2	145	2	2971615
Pubmed	Deletion of the fcgamma receptor IIb in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis.	FCGR2A FCGR2B	1.73e-05	2	145	2	12937154
Pubmed	Identification, molecular cloning, biologic properties, and tissue distribution of a novel isoform of murine low-affinity IgG receptor homologous to human Fc gamma RIIB1.	FCGR2A FCGR2B	1.73e-05	2	145	2	8683114
Pubmed	A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling.	FCGR2A FCGR2B	1.73e-05	2	145	2	8107887
Pubmed	Identification, in mouse macrophages and in serum, of a soluble receptor for the Fc portion of IgG (Fc gamma R) encoded by an alternatively spliced transcript of the Fc gamma RII gene.	FCGR2A FCGR2B	1.73e-05	2	145	2	8398981
Pubmed	Antibody modulation of antigen presentation: positive and negative effects on presentation of the tetanus toxin antigen via the murine B cell isoform of FcgammaRII.	FCGR2A FCGR2B	1.73e-05	2	145	2	11828370
Cytoband	Ensembl 112 genes in cytogenetic band chr2q34	KANSL1L ERBB4 UNC80	3.97e-04	45	145	3	chr2q34
Cytoband	4q31.22	ZNF827 REELD1	4.38e-04	10	145	2	4q31.22
GeneFamily	ATP binding cassette subfamily A	ABCA4 ABCA7 ABCA6	3.90e-05	14	88	3	805
GeneFamily	WD repeat domain containing\|BEACH domain containing	NBEA LYST	8.25e-04	9	88	2	1230
GeneFamily	LIM class homeoboxes	LHX1 LHX2	1.50e-03	12	88	2	522
CoexpressionAtlas	DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_1000	BNC2 GAPVD1 TRIO BAZ2B NBEA CLSTN2 MAU2 ZMIZ1 LYSMD3 BIRC6 TIPARP LHX1 NFIC PRRC2C STARD9 PCDH11X EMX2 NFAT5 TNS1 UTY	2.78e-07	801	139	20	gudmap_developingGonad_e14.5_ epididymis_1000
CoexpressionAtlas	DevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_1000	BNC2 GAPVD1 TRIO NBEA MAU2 ZMIZ1 LYSMD3 BIRC6 TIPARP LHX1 HHIP NFIC PRRC2C STARD9 PCDH11X EMX2 NFAT5 TNS1 UTY	9.95e-07	790	139	19	gudmap_developingGonad_e16.5_epididymis_1000
CoexpressionAtlas	DevelopingGonad_e11.5_testes_emap-3226_top-relative-expression-ranked_1000	MAPK8IP1 BNC2 TRIO BAZ2B DVL2 MAU2 TIPARP LHX1 LHX2 BRCA1 PTPRG NFIC PRRC2C LRP2 EMX2 PLEKHO1 TNS1	3.77e-05	843	139	17	gudmap_developingGonad_e11.5_testes_1000
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	MAGI1 ERBB4 TRIO BAZ2B TBC1D5 NBEA CLASP2 SIK3 BIRC6 UTY	1.12e-09	199	145	10	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	renal_cortex_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	FOXO1 MAGI1 BNC2 ERBB4 TRIO TBC1D5 SIK3 PTPRG LRP2	1.43e-08	192	145	9	e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a
ToppCell	distal-Hematologic-Myeloid_Dendritic_Type_1-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	PLEKHG2 FCGR2C FCGR2B NFKB1 SIGLEC10 GNA15 EMX2 PLEKHO1 C17orf107	1.95e-08	199	145	9	78e70852acda95d2c770cdd539a46b291f929a78
ToppCell	renal_medulla_nuclei\|World / Celltypes from Cells and Nuclei per compartment and clinical group	MAGI1 KANSL1L ERBB4 TBC1D5 SIK3 FRY NFAT5 UTY	2.04e-07	189	145	8	830d9cd0dd706bce22eb2416f07b2c31c870a05a
ToppCell	COVID-19-COVID-19_Mild-Others-RBC\|COVID-19_Mild / Disease, condition lineage and cell class	SWT1 THAP10 PTPRG ABCA6 NPRL3 TRAK2 TNS1 DMTN	2.79e-07	197	145	8	3bae601e5d9689ea57e923814af8cdcae690becc
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	MAGI1 KANSL1L ERBB4 TRIO TBC1D5 SIK3 PTPRG GAB1	2.90e-07	198	145	8	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	distal-2-Hematologic-Myeloid_Dendritic_Type_1\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CLSTN2 FCGR2C FCGR2B NFKB1 SIGLEC10 GNA15 EMX2 PLEKHO1	3.02e-07	199	145	8	86ee039189c75e66b97453c20a34d7fb5a31e51d
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	CCDC14 GAPVD1 SEMA7A GNPTAB BIRC6 NFAT5 UTY	2.63e-06	186	145	7	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TRMT9B PITPNM2 BNC2 ERBB4 TRIO PLEKHG2 PTPRG	2.92e-06	189	145	7	8c8ca3b30d9be6c854615459a7bfba82b427c8bc
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	TRMT9B PITPNM2 BNC2 ERBB4 TRIO PLEKHG2 PTPRG	2.92e-06	189	145	7	5d902a4660a27548764bf04c6de152b565da835c
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Thick_Ascending_Limb_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TRMT9B PITPNM2 KANSL1L BNC2 ERBB4 PRAG1 COBL	3.36e-06	193	145	7	f42a0f02ed00fe1bb833ff0a0640d9131bca89bd
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TRMT9B PITPNM2 KANSL1L BNC2 ERBB4 PRAG1 COBL	3.36e-06	193	145	7	42df7ed37d11fb542b4d1d714b6f87ae8e1396a6
ToppCell	Bronchial-NucSeq\|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations	MAGI1 KANSL1L ERBB4 TBC1D5 SIK3 PTPRG GAB1	3.72e-06	196	145	7	ab53c742866945545a92e2e61850d63c80d9a2a6
ToppCell	distal-Hematologic-Myeloid_Dendritic_Type_1\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	SEMA7A FCGR2B NFKB1 SIGLEC10 GNA15 EMX2 PLEKHO1	4.11e-06	199	145	7	6fc8c321e2ddd802b9c8edfe16e006c7d4d862fc
ToppCell	kidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	KANSL1L PLOD3 POMT1 TXNDC11 PRDM10 PRRC2C UTY	4.11e-06	199	145	7	174f6013af6eafa577f84205a62927f2b367fda3
ToppCell	LPS_IL1RA-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	PITPNM2 TRIO BAZ2B BIRC6 LEPR PTPRG PLEKHO1	4.25e-06	200	145	7	dccec522ab0d7fff62ad6273b02aa9022dbbb8eb
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)-D122\|Adult / Lineage, Cell type, age group and donor	PITPNM2 MAGI1 ERBB4 PTPRG UTY FAM149A	1.28e-05	157	145	6	31d1bd9138c60e8485664ec4144f987226e3eef9
ToppCell	Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_2-Dcn_2_1-Endothelial_Tip.Dcn.Nnat_(Nnat)\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	BNC2 ABCA4 ARSI TP63 KCNJ13	1.49e-05	95	145	5	3699ea16660a22ea79fecfea56ece2dfb0f13467
ToppCell	Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_2-Dcn_2_1\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	BNC2 ABCA4 ARSI TP63 KCNJ13	1.49e-05	95	145	5	cbfe615d880913bafaf5e7e8d24c3ec14a9351ce
ToppCell	Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_2-Dcn_2_1-Endothelial_Tip.Dcn.Nnat_(Nnat)-\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	BNC2 ABCA4 ARSI TP63 KCNJ13	1.49e-05	95	145	5	27ac23b87747434a3084cc087e7b884e68f0eab9
ToppCell	wk_08-11-Mesenchymal-Fibroblast-Alveolar_fibro\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	ZIM2 MAU2 MALRD1 ABCA6 PCDH11X UNC80	1.75e-05	166	145	6	65dafed953b01a9830b54309af75c7a561e88336
ToppCell	E16.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial-Mesothelial_prolif\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	BNC2 AOC2 MUC16 HHIP LRP2 EMX2	2.29e-05	174	145	6	4da79da7a09ee1e345102c5331675ebcdbe56171
ToppCell	PND07-Epithelial-Epithelial_Alveolar-Epithelial_Alveolar-AT2-AT2_G2M\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	SPRY2 TEX15 BUB1 LRP2 COBL SDC1	2.52e-05	177	145	6	a68c3688f12aee22f3cb4049c4bccacbacb0fae6
ToppCell	Fetal_29-31_weeks-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	MAGI1 ERBB4 UBN2 TXNDC11 SDC1 FAM149A	2.68e-05	179	145	6	815b959ce8721c5ded70c0ca6e318dafc691746e
ToppCell	5'-Adult-Appendix-Hematopoietic-Myeloid-LYVE1+_Macrophage\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	OLAH PLEKHG2 FCGR2C SIGLEC10 GNA15 GABBR1	2.77e-05	180	145	6	66c7b02d85e32ba3e7530d0c4aff17e7525ccdd8
ToppCell	droplet-Lung-nan-3m-Epithelial\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	INTU TEX15 MISP ZNF827 LRP2 SPINDOC	2.94e-05	182	145	6	cfba75c1ffc39ac76db9e8e27394731942882b30
ToppCell	droplet-Lung-nan-3m-Epithelial-Alveolar_Epithelial_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	INTU TEX15 MISP ZNF827 LRP2 SPINDOC	2.94e-05	182	145	6	d836bfdc298ecd3558a973e393a329eb8bd59d79
ToppCell	droplet-Lung-LUNG-1m-Epithelial-type_II_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TEX15 MISP KCNJ13 LRP2 COBL SDC1	2.94e-05	182	145	6	c1e0be27064e14043b78ae501b02d4e9542267a3
ToppCell	droplet-Lung-nan-3m-Epithelial-type_II_pneumocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	INTU TEX15 MISP ZNF827 LRP2 SPINDOC	2.94e-05	182	145	6	7e7c7a26460d3003cdf0c0ffb96208a566aa09a7
ToppCell	droplet-Lung-LUNG-1m-Epithelial-Alveolar_Epithelial_Type_2\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TEX15 MISP KCNJ13 LRP2 COBL SDC1	2.94e-05	182	145	6	3c9b4869d357884ae4bcd22a9872faf83a5cfc6d
ToppCell	Calu_3-infected\|Calu_3 / Cell line, Condition and Strain	SEMA7A TRIO BAZ2B TIPARP CEP350 NFAT5	3.04e-05	183	145	6	8f7f5000645f24f20a8d7700c4df1f8953a1780b
ToppCell	IPF-Lymphoid-ILC_B\|Lymphoid / Disease state, Lineage and Cell class	PITPNM2 ZMIZ1 FRY NFKB1 GNA15 GAB1	3.04e-05	183	145	6	9b507547e6adf78e46e7f542cd9958224ec5826a
ToppCell	droplet-Lung-1m-Epithelial-alveolar_epithelial-type_II_pneumocyte-type_2_alveolar_epithelial_cell\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TEX15 MISP KCNJ13 LRP2 COBL SDC1	3.13e-05	184	145	6	24cbe9f2461ea920954e44bf3b2c2a6a5d4debfb
ToppCell	droplet-Lung-1m-Epithelial-alveolar_epithelial-type_II_pneumocyte\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TEX15 MISP KCNJ13 LRP2 COBL SDC1	3.13e-05	184	145	6	98079fd048a63b51bbdf3833b6f15bf0ae99ea90
ToppCell	droplet-Lung-1m-Epithelial-alveolar_epithelial\|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TEX15 MISP KCNJ13 LRP2 COBL SDC1	3.13e-05	184	145	6	86c1551c4f7c7d0c35c14852b01b1e602fa5092a
ToppCell	IPF-Epithelial-ATII\|IPF / Disease state, Lineage and Cell class	MAGI1 ERBB4 HHIP PTPRG LRP2 SDC1	3.23e-05	185	145	6	563b4e6d92bb5d77a3829556116a8e99aebac615
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	GAPVD1 SEMA7A GNPTAB BIRC6 NFAT5 UTY	3.23e-05	185	145	6	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	IPF-Epithelial-ATII\|World / Disease state, Lineage and Cell class	MAGI1 ERBB4 HHIP PTPRG LRP2 SDC1	3.33e-05	186	145	6	6a4ff2da0af0f5e590d9f9daa5b5e9ac8c868947
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	FOXO1 TRMT9B BNC2 ABCA4 PTPRG COBL	3.53e-05	188	145	6	af740fa78542438fdff627ea1f74f4eee43316be
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	BNC2 TRIO CLSTN2 LPIN2 LRP2 TNS1	3.64e-05	189	145	6	3b48b0d220cc24d5170713d61fa91f5bb6c21841
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 RNPC3 LHX1 ABCA6 COBL GAB1	3.64e-05	189	145	6	e32172ad09e93f6ac6ea2b92145b2b73003f7970
ToppCell	renal_cortex_nuclei-Adult_normal_reference\|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group	FOXO1 RNPC3 TIPARP CRYL1 PRRC2C UTY	3.64e-05	189	145	6	a48df46274d51e84ffb40264646de7346104efb9
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Deuterosomal-Deuterosomal_L.0.3.4.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CCDC14 MUC16 MUC12 LHX2 BRCA1 TESMIN	3.75e-05	190	145	6	0adb24dafa077156bbc73a8d8cbf3d9eeb6e08df
ToppCell	NS-moderate-d_16-33-Epithelial-FOXN4+\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	CCDC14 INTU MUC12 BRCA1 TESMIN BUB1	3.75e-05	190	145	6	250ca4a605c1cccd77d23383e4fe6f91cf3609ba
ToppCell	3'_v3-Lung-Myeloid_Dendritic-DC2\|Lung / Manually curated celltypes from each tissue	SEMA7A ABCA6 FCGR2B NFKB1 GNA15 PLEKHO1	3.75e-05	190	145	6	468525c05e38158a3b8a445882b2d63dfb1d2c63
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Deuterosomal\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CCDC14 MUC16 MUC12 LHX2 BRCA1 TESMIN	3.75e-05	190	145	6	05455775845f4ded5c27e7b83242078d23162aaf
ToppCell	LAM-Epithelial-AT1\|LAM / Condition, Lineage and Cell class	MAGI1 ABCA7 MISP COBL TNS1 SDC1	3.86e-05	191	145	6	66875b2ec2c510489407f3e433a90cdf74a15094
ToppCell	CD8+_Memory_T_cell-CV-7\|CD8+_Memory_T_cell / cell class, Virus stimulation and cluster	GAPVD1 GNPTAB BIRC6 LYST NFAT5 UTY	3.86e-05	191	145	6	9454f642c3621370fa23640b631301346b300950
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_2-D122\|Adult / Lineage, Cell type, age group and donor	MAGI1 ERBB4 HHIP PTPRG LRP2 UTY	3.97e-05	192	145	6	06013a07e3a873b1d1c0451643c528593ac32a9c
ToppCell	mild_COVID-19-RBC\|World / disease group, cell group and cell class (v2)	ZBTB26 NPRL3 TNS1 UTY DMTN	4.07e-05	117	145	5	85210be67ddc31903764b7fa6d7029d9656753d3
ToppCell	distal-Hematologic-Basophil/Mast_2-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	SEMA7A ARSI MALRD1 TESMIN BUB1 C17orf107	4.09e-05	193	145	6	f22d0a2ea6bbdd625909ccb6a89aca89ab670306
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	FOXO1 TRIO TBC1D5 SIK3 BIRC6 NFAT5	4.09e-05	193	145	6	779276e775cb2492e8dd36436295a536084a6415
ToppCell	facs-Skin-Anagen-3m-Epithelial-bulge_keratinocyte\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAPK8IP1 BNC2 ZMIZ1 THSD1 LHX2 SDC1	4.09e-05	193	145	6	eba3c70701b051bc1ed1f4db9270cb27a77ffc3e
ToppCell	distal-Hematologic-Basophil/Mast_2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	SEMA7A ARSI MALRD1 TESMIN BUB1 C17orf107	4.09e-05	193	145	6	dcdc1498726c68bf590bf84cb81e5f7fb7ba4d78
ToppCell	distal-3-Hematologic-Basophil/Mast_2\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	SEMA7A ARSI MALRD1 TESMIN BUB1 C17orf107	4.09e-05	193	145	6	23c6c798525dad43eff792727902ea562bf373be
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	MAGI1 KANSL1L ERBB4 CRYL1 LRP2 COBL	4.09e-05	193	145	6	3866667dd221612589ae50f5c52f73a183a49ce6
ToppCell	facs-Thymus-nan-3m\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KANSL1L LYST ARSI WAC PRRC2C UTY	4.21e-05	194	145	6	f1661f9f2439fca5c1012c693b0744c4e3b90a9b
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 TRIO KIZ LHX1 COBL NFAT5	4.21e-05	194	145	6	46070fbb0ee0eb9e1801c43b73a15707471056dc
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 TRIO KIZ LHX1 COBL NFAT5	4.21e-05	194	145	6	abacb6a8d7a9003f2f6c2be0305507f1c1c50347
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MAGI1 KANSL1L BNC2 ERBB4 PRAG1 COBL	4.21e-05	194	145	6	e577d9e88390b36b5a09b97fe1026089892275a3
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	MAGI1 KANSL1L ERBB4 ZNF827 LRP2 COBL	4.21e-05	194	145	6	7002937e8903e037332a215d00fbc7c7843b33f2
ToppCell	facs-Thymus-nan\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KANSL1L LYST ARSI WAC PRRC2C UTY	4.21e-05	194	145	6	cda1b197efb199330ea7ab25a7cee22cae22589d
ToppCell	10x_3'_v2v3-Neoplastic-Differentiated-like-AC-like-AC-like-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SPRY2 ERBB4 TRIO LHX2 NSUN6 MALRD1	4.21e-05	194	145	6	68d15917ae222cba0ad9e716d29eebb6c5f00f69
ToppCell	390C-Myeloid-Dendritic-cDC2\|390C / Donor, Lineage, Cell class and subclass (all cells)	FCGR2A FCGR2B NFKB1 GNA15 NFAT5 PLEKHO1	4.21e-05	194	145	6	705fa653c11b6c8a427e007533aa4a4bb5845078
ToppCell	facs-Thymus-nan-3m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KANSL1L LYST ARSI WAC PRRC2C UTY	4.21e-05	194	145	6	66c056232ac216780acf4cc8ea325bd8ed1909c9
ToppCell	facs-Skin-Anagen-3m-Epithelial-outer_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MAPK8IP1 BNC2 ZMIZ1 THSD1 LHX2 SDC1	4.21e-05	194	145	6	5d30d3d41d5f19cdf3077cc609aa2738762cb8c5
ToppCell	moderate-Epithelial-FOXN4+\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	CCDC14 MUC12 CEP350 BRCA1 TESMIN BUB1	4.21e-05	194	145	6	dff3fb10372053951d41e0ccd41aac3ece6009bd
ToppCell	medial-2-Hematologic-Myeloid_Dendritic_Type_2\|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CLSTN2 FCGR2C FCGR2A FCGR2B SIGLEC10 PLEKHO1	4.33e-05	195	145	6	54a404ee1b97d0659fcffafb20d11f878ed453d4
ToppCell	medial-Hematologic-Myeloid_Dendritic_Type_2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CLSTN2 FCGR2C FCGR2A FCGR2B SIGLEC10 PLEKHO1	4.33e-05	195	145	6	c0d1ecb378bb482a8e08d7065fcca07a65687dac
ToppCell	medial-Hematologic-Myeloid_Dendritic_Type_2-2\|medial / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	CLSTN2 FCGR2C FCGR2A FCGR2B SIGLEC10 PLEKHO1	4.33e-05	195	145	6	35a5302b8b3e76bc92dc38979400c979f0e86550
ToppCell	facs-Skin-Telogen-3m-Epithelial-outer_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	BNC2 ZMIZ1 THSD1 LHX2 TNS1 SDC1	4.45e-05	196	145	6	c936014125b2ed5f796221b74acb77b8f8359875
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-CD4/CD8-CD8_EM-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	SPRY2 RNPC3 MUC16 ZBTB26 ZNF350 TNS1	4.45e-05	196	145	6	7e98380d815fbf6254289ace2af37aac6fef51e8
ToppCell	10x3'2.3-week_17-19-Hematopoietic-erythroid-mid_erythroid\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	SEMA7A LPIN2 NPRL3 TRAK2 TNS1 DMTN	4.45e-05	196	145	6	51c48944149a89b98011a50fe81ca6664d5f0d44
ToppCell	LPS_IL1RA_TNF\|World / Treatment groups by lineage, cell group, cell type	VARS2 ARSI ABCA6 COBL TNS1 UTY	4.58e-05	197	145	6	0a6550dce156fc81f15b1e7830d331ca50d87d06
ToppCell	mild-Plasmablast\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	TEX14 TXNDC11 PTPRG BUB1 SDC1 GAB1	4.58e-05	197	145	6	21085d5e27b5a23a241a933058bb89f8a1fcf198
ToppCell	distal-3-Endothelial-Bronchial_Vessel_2\|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MAGI1 NBEA PLEKHG2 LYSMD3 LEPR PTPRG	4.71e-05	198	145	6	f701d06e3d7fd2192afae3698c5ec3c355e96da3
ToppCell	severe-Plasmablast\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	TEX14 TXNDC11 FCGR2B BUB1 SDC1 GAB1	4.71e-05	198	145	6	0b1620ad4352ee5d599a72931aaceab4ca407498
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NBEA GRIN2A FRY PCDH11X MTUS2 UNC80	4.71e-05	198	145	6	8ab40fae14fe02e39bc8c8da187a5cd60c787643
ToppCell	distal-1-Hematologic-Myeloid_Dendritic_Type_2\|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	FCGR2C FCGR2B MPP4 SIGLEC10 PLEKHO1 MTUS2	4.71e-05	198	145	6	5b27949ac3fc7eb34949f9f360d57e6ae82a2368
ToppCell	LPS_IL1RA-Epithelial_alveolar-AT_1\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	ABCA4 MISP LPIN2 PCDH11X COBL SDC1	4.85e-05	199	145	6	a270630626df614f8605abddb7dee7c4d74f6149
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_perichondrial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	BNC2 LEPR TIPARP PTPRG ABCA6 PCDH11X	4.98e-05	200	145	6	a4ec0e80f5422b91b85264a9bb74568dd577e285
ToppCell	Control_saline-Endothelial-Endothelial-Gen_Cap\|Control_saline / Treatment groups by lineage, cell group, cell type	PITPNM2 BAZ2B THSD1 LEPR PTPRG PLEKHO1	4.98e-05	200	145	6	3b97920e1e6e2f09ddba2a861baa9c00c2970f4c
ToppCell	LPS_anti-TNF-Endothelial-Endothelial-Gen_Cap\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	PITPNM2 BAZ2B THSD1 LEPR PTPRG PLEKHO1	4.98e-05	200	145	6	a2b9d1cd291d17abddc3ee2e242121412c864b8b
ToppCell	Tracheal-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	BNC2 LEPR PTPRG ABCA6 STARD9 TNS1	4.98e-05	200	145	6	c318d14bd6fd6f42c597eb55ac9e2f48008aeb9b
ToppCell	LPS_IL1RA_TNF-Endothelial-Endothelial-Gen_Cap\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	PITPNM2 BAZ2B THSD1 LEPR PTPRG PLEKHO1	4.98e-05	200	145	6	b2d4e6f3e8e4da62e6b02758ab2ed8f505269f9a
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_adventitial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	BNC2 CLSTN2 LEPR PTPRG ABCA6 STARD9	4.98e-05	200	145	6	0c25d56292b9e5fefa4521b72635449be1ffd6fe
ToppCell	LPS-antiTNF-Epithelial_alveolar-Mes-Like-Differentiating_AT1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	IFT140 ABCA4 PRAG1 TESMIN SDC1	6.24e-05	128	145	5	2cf0384240a4a663869cf6b27d954236f6214a9a
ToppCell	RV-14._Fibroblast_III\|RV / Chamber and Cluster_Paper	NLGN4Y CLSTN2 ABCA6 KCNJ13 EMX2	9.54e-05	140	145	5	b4fee8eb6bf855b364b00bda3f78e49d851bbca0
ToppCell	390C-Myeloid-Macrophage-SPP1+_Macrophage_3\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	THSD1 MROH8 FCGR2A FCGR2B PCDH11X	1.28e-04	149	145	5	13b445c13bb8f31ff0876addd1baf969ae220ea3
ToppCell	Posterior_cortex-Endothelial-ENDOTHELIAL_TIP-Dcn_2\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	BNC2 ABCA4 FIGNL2 ARSI KCNJ13	1.45e-04	153	145	5	151c469b26f9adf04dd6f117f03bef760cc3d45d
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-CR\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TEX15 LHX1 EMX2 SDC1	1.56e-04	83	145	4	1ab68323518adc7fd0a459b41fad12d60f97eb5c
ToppCell	primary_visual_cortex-Neuronal-glutamatergic_neuron-CR-CR_Lhx5\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TEX15 LHX1 EMX2 SDC1	1.56e-04	83	145	4	75b27d91a4473286f4b40027e96ac5246f5abe5b
ToppCell	Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Neuronal-cortical_neurons_1\|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type.	TRIO CLASP2 GRIN2A UNC80 DMTN	1.68e-04	158	145	5	1f94622186d8329357fa06785e03eeacf29ab1ce
ToppCell	356C-Lymphocytic-CD4_T-cell-Treg_cell_4\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	MED16 AOC2 TP63 PCDH11X SPINDOC	1.78e-04	160	145	5	c2b5fadb4bac17fafc08831f6d3f4ff96ada7e70
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_loop_of_Henle_thick_ascending_limb_epithelial_cell-Macula_Densa_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	ERBB4 ZIM2 PRAG1 LYST MTUS2	1.89e-04	162	145	5	373513f9d0e5007b2e10a8b78d4909dcce9e3b62
ToppCell	Adult-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)\|Adult / Lineage, Cell type, age group and donor	PITPNM2 MAGI1 ERBB4 PTPRG FAM149A	1.94e-04	163	145	5	e819a1d6d28290854aa0672b3a18fa9e293d8f23
ToppCell	wk_08-11-Mesenchymal-Myofibro_&_SMC-Late_airway_SMC\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	PITPNM2 CLSTN2 HHIP STARD9 COBL	1.94e-04	163	145	5	1e8730d75cccf7292010683ab4e81a69d8e3bfa9
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW19-Neuronal-GABAergic_neurons\|GW19 / Sample Type, Dataset, Time_group, and Cell type.	ERBB4 PCDH11X COBL UNC80	1.96e-04	88	145	4	5582fd7bac60c690ecd1f2aff1d446ccb69f79b9
ToppCell	droplet-Lung-18m-Hematologic-lymphocytic-plasma_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TXNDC11 BRCA1 ZNF827 BUB1 SDC1	2.00e-04	164	145	5	b92e7c91910d518627376166c6ea9ed333b3d07e
ToppCell	droplet-Lung-18m-Hematologic-lymphocytic-plasma_cell-plasma_cell\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TXNDC11 BRCA1 ZNF827 BUB1 SDC1	2.00e-04	164	145	5	a1e43c6b3e2553f5604100db6e92bf244b70c36d
Drug	MDL 20,610	FCGR2C FCGR2A FCGR2B	2.30e-06	5	141	3	CID000128209
Drug	Pyrantel tartrate [33401-94-4]; Up 200; 11.2uM; MCF7; HT_HG-U133A	TRMT9B GPR15 TBC1D5 TEX15 LEPR PRDM10 TESMIN TNS1 GAB1	3.64e-06	195	141	9	2260_UP
Drug	Thioproperazine dimesylate [2347-80-0]; Down 200; 6.2uM; MCF7; HT_HG-U133A	SPN MED16 THSD1 LEPR LHX1 ARNT NFIC NPRL3 LRP2	3.80e-06	196	141	9	2236_DN
Drug	Orphenadrine hydrochloride [341-69-5]; Down 200; 13uM; PC3; HT_HG-U133A	SEMA7A TRIO RASA3 AOC2 DVL2 THSD1 NFIC PLEKHO1 TNS1	3.96e-06	197	141	9	3801_DN
Drug	2-propylpentanoic acid; Up 200; 1000uM; PC3; HT_HG-U133A	IFT140 GPR15 SEMA7A TRIO SPN MED16 MAU2 ARNT GAB1	3.96e-06	197	141	9	4433_UP
Drug	Dimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; HL60; HT_HG-U133A	MAGI1 MED16 NBEA ABCA7 LEPR ARNT TESMIN MYO15A GAB1	3.96e-06	197	141	9	2151_UP
Drug	Propylthiouracil [51-52-5]; Down 200; 23.4uM; PC3; HT_HG-U133A	KANSL1L IFT140 TRIO ARNT BUB1 ZNF839 TNS1 UTY DMTN	4.48e-06	200	141	9	4076_DN
Drug	TAN-1030A	FCGR2C FCGR2A FCGR2B	4.59e-06	6	141	3	CID009576886
Drug	AC1MHTIN	FCGR2C FCGR2A FCGR2B	7.99e-06	7	141	3	CID003011133
Drug	TAN-999	FCGR2C FCGR2A FCGR2B	7.99e-06	7	141	3	CID000130283
Drug	Intravenous Immunoglobulin	FCGR2C FCGR2A FCGR2B	1.27e-05	8	141	3	DB00028
Drug	AC1NSK5W	FCGR2C FCGR2A FCGR2B	1.90e-05	9	141	3	CID005311182
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	FOXO1 TRIO KAT6A THSD1 CEP350 PDE12 LRP2 NFAT5	2.59e-05	191	141	8	4279_DN
Drug	CP-319743 [172078-87-4]; Up 200; 10uM; MCF7; HT_HG-U133A	TRIO TBC1D5 LHX2 ARNT PDE12 TESMIN ZNF350 UTY	2.59e-05	191	141	8	7486_UP
Drug	Palivizumab	FCGR2C FCGR2A FCGR2B	2.70e-05	10	141	3	DB00110
Drug	Denny-Jaffe reagent	FCGR2C FCGR2A FCGR2B	2.70e-05	10	141	3	CID003035979
Drug	Pyrilamine maleate [59-33-6]; Down 200; 10uM; MCF7; HT_HG-U133A	FOXO1 MAGI1 SPN BAZ2B THSD1 ARNT UTY DMTN	2.90e-05	194	141	8	3184_DN
Drug	Aminophylline [317-34-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A	KANSL1L RASA3 ABCA7 LEPR LHX1 PDE12 TESMIN GAB1	3.12e-05	196	141	8	3374_DN
Drug	Acetopromazine maleate salt [3598-37-6]; Up 200; 9uM; MCF7; HT_HG-U133A	TRMT9B KANSL1L HNF1A MED16 BUB1 MYO15A TNS1 FAM149A	3.12e-05	196	141	8	6832_UP
Drug	Nitrarine dihydrochloride [20069-05-0]; Up 200; 10.6uM; MCF7; HT_HG-U133A	ERBB4 SPN RASA3 KAT6A ABCA7 LRP2 GNA15 TNS1	3.23e-05	197	141	8	6043_UP
Drug	Pheniramine maleate [132-20-7]; Up 200; 11.2uM; MCF7; HT_HG-U133A	SPRY2 RASA3 MED16 ABCA7 LEPR ARNT PDE12 BUB1	3.23e-05	197	141	8	4130_UP
Drug	Gelsemine [509-15-9]; Down 200; 12.4uM; MCF7; HT_HG-U133A	MED16 DVL2 ZIM2 TEX14 THSD1 ARNT BUB1 TNS1	3.23e-05	197	141	8	4177_DN
Drug	DNA-PK Inhibitor III; Down 200; 1uM; MCF7; HT_HG-U133A	MED16 KAT6A DVL2 CLSTN2 LEPR ZNF350 NFAT5 GAB1	3.23e-05	197	141	8	7543_DN
Drug	Zoxazolamine [61-80-3]; Down 200; 23.8uM; MCF7; HT_HG-U133A	TRIO TBC1D5 THSD1 LYST ARNT PDE12 ZNF350 UTY	3.35e-05	198	141	8	5390_DN
Drug	LY 294002; Up 200; 0.1uM; HL60; HT_HG-U133A	KANSL1L BNC2 THSD1 LYST CRYL1 ARNT LRP2 ZNF839	3.35e-05	198	141	8	1157_UP
Drug	Mebendazole [31431-39-7]; Down 200; 13.6uM; PC3; HT_HG-U133A	TRIO BAZ2B CLASP2 POMT1 NPRL3 ZNF350 UTY ZMYM4	3.35e-05	198	141	8	7370_DN
Drug	Drofenine hydrochloride [548-66-3]; Down 200; 11.4uM; HL60; HT_HG-U133A	FOXO1 OLAH SPN MED16 DVL2 NBEA TNS1 UTY	3.35e-05	198	141	8	2714_DN
Drug	Budesonide [51333-22-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	MAGI1 KANSL1L DVL2 CLASP2 PDE12 NFAT5 UTY DMTN	3.35e-05	198	141	8	5431_DN
Drug	Trazodone hydrochloride [25332-39-2]; Down 200; 9.8uM; MCF7; HT_HG-U133A	FOXO1 SPN CLASP2 SMG5 LHX2 LPIN2 NFAT5 PLEKHO1	3.47e-05	199	141	8	7452_DN
Drug	Meprylcaine hydrochloride [956-03-6]; Up 200; 14.8uM; MCF7; HT_HG-U133A	IFT140 ERBB4 RASA3 CLSTN2 LHX2 TESMIN TNS1 FAM149A	3.47e-05	199	141	8	3544_UP
Drug	Clozapine [5786-21-0]; Down 200; 12.2uM; MCF7; HT_HG-U133A	GNPTAB AOC2 ABCA7 CEP350 LHX1 TP63 LRP2 DMTN	3.47e-05	199	141	8	5265_DN
Drug	Cyclopenthiazide [742-20-1]; Down 200; 10.6uM; HL60; HT_HG-U133A	FOXO1 BNC2 SPN THAP10 SMG5 LHX2 NFIC UTY	3.60e-05	200	141	8	2905_DN
Drug	2-Aminobenzenesulfonamide [3306-62-5]; Up 200; 23.2uM; PC3; HT_HG-U133A	TRIO TBC1D5 SAMD4B AOC2 DVL2 CEP350 BUB1 PLEKHO1	3.60e-05	200	141	8	6321_UP
Drug	Carteolol hydrochloride [51781-21-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	TRIO RASA3 CLASP2 CLSTN2 LHX2 ARNT PDE12 UTY	3.60e-05	200	141	8	3276_DN
Drug	Bevacizumab	FCGR2C FCGR2A FCGR2B	3.70e-05	11	141	3	DB00112
Drug	Tositumomab	FCGR2C FCGR2A FCGR2B	3.70e-05	11	141	3	DB00081
Drug	Alemtuzumab	FCGR2C FCGR2A FCGR2B	3.70e-05	11	141	3	DB00087
Drug	Efalizumab	FCGR2C FCGR2A FCGR2B	3.70e-05	11	141	3	DB00095
Drug	Alefacept	FCGR2C FCGR2A FCGR2B	3.70e-05	11	141	3	DB00092
Drug	Daclizumab	FCGR2C FCGR2A FCGR2B	4.91e-05	12	141	3	DB00111
Drug	Natalizumab	FCGR2C FCGR2A FCGR2B	4.91e-05	12	141	3	DB00108
Drug	Rituximab	FCGR2C FCGR2A FCGR2B	4.91e-05	12	141	3	DB00073
Drug	Ibritumomab	FCGR2C FCGR2A FCGR2B	4.91e-05	12	141	3	DB00078
Drug	Adalimumab	FCGR2C FCGR2A FCGR2B	4.91e-05	12	141	3	DB00051
Drug	Gemtuzumab ozogamicin	FCGR2C FCGR2A FCGR2B	4.91e-05	12	141	3	DB00056
Drug	Cetuximab	FCGR2C FCGR2A FCGR2B	4.91e-05	12	141	3	DB00002
Drug	3,5-diaminocyclohexan-1-ol	HNF1A SPN FCGR2C FCGR2A FCGR2B	6.02e-05	67	141	5	CID004632239
Drug	Trastuzumab	FCGR2C FCGR2A FCGR2B	6.35e-05	13	141	3	DB00072
Drug	Basiliximab	FCGR2C FCGR2A FCGR2B	6.35e-05	13	141	3	DB00074
Drug	Abciximab	FCGR2C FCGR2A FCGR2B	8.05e-05	14	141	3	DB00054
Drug	Etanercept	FCGR2C FCGR2A FCGR2B	8.05e-05	14	141	3	DB00005
Drug	Lanatoside C [17575-22-3]; Up 200; 4uM; HL60; HT_HG-U133A	KANSL1L HIVEP1 KAT6A SMG5 MAU2 TIPARP PRDM10	9.00e-05	169	141	7	2193_UP
Drug	Muromonab	FCGR2C FCGR2A FCGR2B	1.00e-04	15	141	3	DB00075
Drug	AC1NS1CY	CLSTN2 FCGR2C FCGR2A FCGR2B	1.08e-04	40	141	4	CID005326941
Drug	cathepsin G inhibitor I	SPN NFIC	1.14e-04	3	141	2	CID009830518
Drug	AC1L9LSE	FCGR2C FCGR2A FCGR2B	1.23e-04	16	141	3	CID000448272
Drug	Trichostatin A, Streptomyces sp.; Down 200; 1uM; HL60; HT_HG-U133A	SPN SMG5 ZMIZ1 LYST NFIC NPRL3 TNS1	1.24e-04	178	141	7	6193_DN
Drug	Etifenin [63245-28-3]; Down 200; 12.4uM; PC3; HT_HG-U133A	TBC1D5 WAC CEP350 NFIC PRRC2C BUB1 NFAT5	1.24e-04	178	141	7	3998_DN
Drug	fluorenone	GRIN2A TP63 DMTN	1.48e-04	17	141	3	CID000010241
Drug	2cgx	FCGR2C FCGR2A FCGR2B	1.77e-04	18	141	3	CID001548380
Drug	Chlorambucil [305-03-3]; Down 200; 13.2uM; PC3; HT_HG-U133A	SEMA7A TRIO KAT6A ARNT PDE12 BUB1 NFAT5	1.80e-04	189	141	7	3788_DN
Drug	Ketanserin tartrate hydrate [83846-83-7]; Down 200; 7uM; PC3; HT_HG-U133A	BNC2 TRIO KAT6A CEP350 ARNT TRAK2 ZNF839	1.80e-04	189	141	7	6649_DN
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; HL60; HT_HG-U133A	WAC BRCA1 PRRC2C BUB1 TRAK2 NFAT5 PLEKHO1	1.80e-04	189	141	7	1288_DN
Drug	Drofenine hydrochloride [548-66-3]; Up 200; 11.4uM; MCF7; HT_HG-U133A	TRMT9B KANSL1L KAT6A LYST TP63 TNS1 DMTN	1.92e-04	191	141	7	6776_UP
Drug	PF-00875133-00 [351322-64-0]; Up 200; 10uM; MCF7; HT_HG-U133A	THSD1 LHX2 GNA15 MYO15A TNS1 UTY DMTN	1.98e-04	192	141	7	5967_UP
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A	FOXO1 MED16 DVL2 ARNT LRP2 ZNF350 NFAT5	2.05e-04	193	141	7	1464_DN
Drug	R13-1	FCGR2C FCGR2A FCGR2B	2.09e-04	19	141	3	CID000009666
Drug	Coralyne chloride hydrate [38989-38-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A	KANSL1L MED16 AOC2 ZIM2 LEPR TP63 DMTN	2.11e-04	194	141	7	5418_UP
Drug	5230742; Up 200; 17uM; MCF7; HT_HG-U133A_EA	TBC1D5 THSD1 LHX1 PDE12 MYO15A GAB1 DMTN	2.11e-04	194	141	7	862_UP
Drug	11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A	FOXO1 MED16 TBC1D5 KAT6A BUB1 LPIN2 UTY	2.11e-04	194	141	7	7538_DN
Drug	Adamantamine fumarate [80789-67-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A	SPRY2 TRIO SPN MED16 CLASP2 THSD1 LYST	2.11e-04	194	141	7	3280_DN
Drug	Flunisolide [3385-03-3]; Up 200; 9.2uM; MCF7; HT_HG-U133A	TRMT9B TRIO KAT6A TEX14 PRDM10 ARNT PDE12	2.18e-04	195	141	7	3828_UP
Drug	Sulmazole [73384-60-8]; Down 200; 14uM; HL60; HT_HG-U133A	FOXO1 BNC2 SPN MED16 SMG5 ARNT ZNF350	2.18e-04	195	141	7	2153_DN
Drug	Nefopam hydrochloride [23327-57-3]; Down 200; 13.8uM; MCF7; HT_HG-U133A	SPN KAT6A DVL2 LEPR LHX1 ARNT ZNF350	2.18e-04	195	141	7	2317_DN
Drug	arachidonyl trifluoromethyl ketone; Down 200; 10uM; MCF7; HG-U133A	FOXO1 SEMA7A TBC1D5 TMEM39B MAU2 ARNT NFIC	2.18e-04	195	141	7	327_DN
Drug	Acacetin [480-44-4]; Down 200; 14uM; PC3; HT_HG-U133A	TRIO SPN SMG5 THSD1 TIPARP NFIC BUB1	2.18e-04	195	141	7	4324_DN
Drug	Cefepime hydrochloride [123171-59-5]; Down 200; 7.4uM; HL60; HT_HG-U133A	SPN TEX15 LYST CEP350 ARNT NFIC PRRC2C	2.18e-04	195	141	7	6159_DN
Drug	Pepstatin A [26305-03-3]; Down 200; 5.8uM; PC3; HT_HG-U133A	TRMT9B IFT140 SPN MED16 MYO15A UTY GAB1	2.25e-04	196	141	7	4206_DN
Drug	Benzbromarone [3562-84-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A	KANSL1L KAT6A DVL2 ARNT ZNF350 ZNF839 PLEKHO1	2.25e-04	196	141	7	5015_DN
Drug	Ribostamycin sulfate salt [53797-35-6]; Up 200; 7.2uM; PC3; HT_HG-U133A	FOXO1 ABCA7 LHX2 PDE12 LRP2 ZNF839 PLEKHO1	2.25e-04	196	141	7	7123_UP
Drug	Timolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A	SPRY2 TBC1D5 TEX14 ARNT TP63 LRP2 DMTN	2.25e-04	196	141	7	5280_DN
Drug	estradiol, USP; Down 200; 0.01uM; ssMCF7; HG-U133A	IFT140 SPN DVL2 ARNT NFIC LPIN2 GAB1	2.25e-04	196	141	7	373_DN
Drug	Naltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; PC3; HT_HG-U133A	MED16 THSD1 LYST PDE12 NPRL3 COBL ZNF839	2.25e-04	196	141	7	5765_DN
Drug	LY294002; Up 200; 0.1uM; MCF7; HG-U133A	SPN SCYL3 DVL2 CLASP2 NFIC TP63 TNS1	2.25e-04	196	141	7	424_UP
Drug	Dizocilpine maleate [77086-22-7]; Down 200; 11.8uM; MCF7; HT_HG-U133A	MAGI1 TRIO MED16 THSD1 LEPR ARNT LRP2	2.25e-04	196	141	7	2232_DN
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; PC3; HT_HG-U133A	AOC2 CEP350 LHX2 ARNT PDE12 TNS1 UTY	2.25e-04	196	141	7	4439_DN
Drug	Idoxuridine [54-42-2]; Down 200; 11.2uM; PC3; HT_HG-U133A	TRMT9B IFT140 MED16 DVL2 ARNT PDE12 GAB1	2.25e-04	196	141	7	4200_DN
Drug	(-)-Eseroline fumarate salt [104015-29-4]; Down 200; 12uM; MCF7; HT_HG-U133A	FOXO1 IFT140 SPN SMG5 ARNT PTPRG UTY	2.25e-04	196	141	7	7027_DN
Drug	Prilocaine hydrochloride [1786-81-8]; Down 200; 15.6uM; MCF7; HT_HG-U133A	KANSL1L IFT140 SEMA7A DVL2 SMG5 ARNT ZNF350	2.25e-04	196	141	7	2314_DN
Drug	Deferoxamine mesylate [138-14-7]; Down 200; 6uM; PC3; HT_HG-U133A	SPN AOC2 THSD1 LYST BUB1 COBL TNS1	2.25e-04	196	141	7	3760_DN
Drug	3-Acetamidocoumarin [779-30-6]; Down 200; 19.6uM; HL60; HT_HG-U133A	SPN THAP10 LHX2 ARNT BUB1 NFAT5 UTY	2.25e-04	196	141	7	2941_DN
Drug	Benfotiamine [22457-89-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A	SEMA7A TRIO RASA3 MED16 GNPTAB ARNT LRP2	2.25e-04	196	141	7	3837_UP
Drug	Quinethazone [73-49-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A	TRMT9B IFT140 MED16 LEPR PDE12 LRP2 GAB1	2.25e-04	196	141	7	3875_UP
Drug	Gliclazide [21187-98-4]; Up 200; 12.4uM; HL60; HG-U133A	FOXO1 BNC2 HNF1A GNPTAB POMT1 NFAT5 PLEKHO1	2.25e-04	196	141	7	1720_UP
Drug	3-deoxyxylosone	TRIO TP63	2.27e-04	4	141	2	CID000277989
Drug	alpha-Santonin [481-06-1]; Up 200; 16.2uM; MCF7; HT_HG-U133A	IFT140 MED16 ZIM2 ABCA7 CIAO1 UTY GAB1	2.32e-04	197	141	7	3877_UP
Drug	Cyclacillin [3485-14-1]; Down 200; 11.8uM; PC3; HT_HG-U133A	SEMA7A TRIO MED16 DVL2 THSD1 ABCA7 TNS1	2.32e-04	197	141	7	3800_DN
Drug	Methylergometrine maleate [113-42-8]; Down 200; 8.8uM; MCF7; HT_HG-U133A	TRIO SPN SMG5 CIAO1 LPIN2 NPRL3 ZNF839	2.32e-04	197	141	7	5303_DN
Drug	ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A	TRMT9B SEMA7A THSD1 LEPR LHX2 TESMIN UTY	2.32e-04	197	141	7	5964_UP
Drug	FK-506; Up 200; 1uM; MCF7; HG-U133A	TRIO SPN ARNT PRRC2C COBL NFAT5 UTY	2.32e-04	197	141	7	284_UP
Disease	malaria (implicated_via_orthology)	FCGR2C FCGR2A FCGR2B	8.60e-06	9	140	3	DOID:12365 (implicated_via_orthology)
Disease	colorectal cancer (is_implicated_in)	HNF1A ERBB4 GRIN2A BRCA1 BUB1 EMX2	2.52e-05	121	140	6	DOID:9256 (is_implicated_in)
Disease	serum albumin measurement	HNF1A HIVEP1 RASA3 SIK3 LEPR FCGR2C FRY ARNT FCGR2A ABCA6 FCGR2B SEMA5B	2.70e-05	592	140	12	EFO_0004535
Disease	aspartate aminotransferase measurement	MAGI1 HNF1A ABCA4 TBC1D5 DVL2 PRAG1 BIRC6 LEPR FCGR2C BRCA1 FCGR2A FCGR2B ZNF827 MYO15A GABBR1	2.73e-05	904	140	15	EFO_0004736
Disease	Colorectal Carcinoma	ABCA4 CLSTN2 GRIN2A ZMIZ1 WAC HHIP ARNT ABCA6 TP63 BUB1 PCDH11X LRP2 ZMYM4	3.16e-05	702	140	13	C0009402
Disease	uric acid measurement	HNF1A INTU ERBB4 SWT1 ZMIZ1 BIRC6 ABCA6 ZNF827 NFKB1 LRP2 EMX2 NFAT5	3.61e-05	610	140	12	EFO_0004761
Disease	Colorectal Neoplasms	ABCA4 GRIN2A ZMIZ1 HHIP ARNT ABCA6 TP63 BUB1	5.59e-05	277	140	8	C0009404
Disease	low affinity immunoglobulin gamma Fc region receptor II-a measurement	FCGR2C FCGR2A FCGR2B	6.77e-05	17	140	3	EFO_0021969
Disease	serum alanine aminotransferase measurement	HNF1A RASA3 SAMD4B DVL2 MAU2 PRAG1 LEPR FCGR2C HHIP FCGR2B ZNF827 SDC1 GABBR1 DMTN	7.02e-05	869	140	14	EFO_0004735
Disease	Female Urogenital Diseases	LHX1 TP63 EMX2	8.10e-05	18	140	3	C1720887
Disease	alkaline phosphatase measurement	HNF1A ZMIZ1 PRAG1 LEPR TXNDC11 WAC FCGR2C ABCA6 FCGR2B SLC4A1AP ZNF827 TONSL NFAT5 C17orf107 GABBR1	1.00e-04	1015	140	15	EFO_0004533
Disease	phenylketonuria (implicated_via_orthology)	HNF1A DUOX2	1.33e-04	4	140	2	DOID:9281 (implicated_via_orthology)
Disease	ovarian carcinoma	BNC2 ERBB4 ABCA4 TIPARP BRCA1 PTPRG TONSL MTUS2	1.55e-04	321	140	8	EFO_0001075
Disease	low affinity immunoglobulin gamma Fc region receptor II-b measurement	FCGR2C FCGR2A FCGR2B	2.23e-04	25	140	3	EFO_0021970
Disease	non-alcoholic fatty liver disease	HNF1A MAU2 ZMIZ1 SIK3 HHIP ZNF827	2.40e-04	182	140	6	EFO_0003095
Disease	SYSTEMIC LUPUS ERYTHEMATOSUS	FCGR2A FCGR2B	3.31e-04	6	140	2	152700
Disease	urate measurement	BNC2 HNF1A ERBB4 VARS2 ZMIZ1 TEX14 BIRC6 MALRD1 ZNF827 NFIC LRP2 EMX2 NFAT5	3.50e-04	895	140	13	EFO_0004531
Disease	mean reticulocyte volume	FOXO1 INTU MAU2 ABCA7 TXNDC11 WAC CEP350 NFKB1 TONSL LPIN2 NPRL3 GNA15	4.42e-04	799	140	12	EFO_0010701
Disease	ovarian neoplasm	BNC2 MUC16 TIPARP BRCA1 TP63	4.58e-04	134	140	5	C0919267
Disease	low affinity immunoglobulin gamma Fc region receptor II-a/b measurement	FCGR2A FCGR2B	4.62e-04	7	140	2	EFO_0008211
Disease	lymphoid leukemia (is_implicated_in)	FCGR2A FCGR2B	4.62e-04	7	140	2	DOID:1037 (is_implicated_in)
Disease	Malignant neoplasm of ovary	BNC2 MUC16 TIPARP BRCA1 TP63	5.06e-04	137	140	5	C1140680
Disease	cathepsin S measurement	GNPTAB ARNT	6.14e-04	8	140	2	EFO_0008073
Disease	cystatin C measurement	BNC2 HNF1A INTU ERBB4 SEMA7A KIZ LRP2 NFAT5	6.93e-04	402	140	8	EFO_0004617
Disease	plexin-B2 measurement	FCGR2C FCGR2B	7.87e-04	9	140	2	EFO_0021867
Disease	mean corpuscular hemoglobin concentration	FOXO1 MAPK8IP1 IFT140 INTU SMG5 MAU2 ABCA7 LEPR ABCA6 FCGR2B NFKB1 NPRL3 GNA15 MYO15A	8.02e-04	1105	140	14	EFO_0004528
Disease	Cleft upper lip	SPRY2 ABCA4 TP63	8.43e-04	39	140	3	C0008924
Disease	neutrophil count	FOXO1 MAGI1 BNC2 HNF1A HIVEP1 PLEKHG2 ZMIZ1 SIK3 TEX14 ABCA7 LEPR LHX2 BRCA1 FCGR2B GNA15 ZMYM4	8.87e-04	1382	140	16	EFO_0004833
Disease	lipid measurement, lipoprotein measurement	HNF1A SIK3 LEPR ABCA6	9.04e-04	90	140	4	EFO_0004529, EFO_0004732
Disease	level of Ceramide (d42:1) in blood serum	MAU2 SIK3	9.81e-04	10	140	2	OBA_2045187
Disease	level of Sterol ester (27:1/18:3) in blood serum	HNF1A MAU2	9.81e-04	10	140	2	OBA_2045193
Disease	Cleft palate, isolated	BNC2 SPRY2 TP63	1.05e-03	42	140	3	C1837218
Disease	systemic lupus erythematosus (implicated_via_orthology)	FCGR2C FCGR2A FCGR2B	1.12e-03	43	140	3	DOID:9074 (implicated_via_orthology)
Disease	squamous cell lung carcinoma	VARS2 PRAG1 FRY TP63 COBL	1.17e-03	165	140	5	EFO_0000708
Disease	Systemic lupus erythematosus	FCGR2A FCGR2B	1.20e-03	11	140	2	cv:C0024141
Disease	guanosine diphosphate measurement	BAZ2B NBEA	1.20e-03	11	140	2	EFO_0010494
Disease	Adenoid Cystic Carcinoma	MAGI1 KAT6A ZIM2 BRCA1	1.34e-03	100	140	4	C0010606
Disease	progression free survival, urinary bladder cancer	IFT140 ERBB4	1.43e-03	12	140	2	EFO_0004920, MONDO_0001187
Disease	Dental enamel hypoplasia	ZMIZ1 SEMA5B	1.43e-03	12	140	2	EFO_1001304
Disease	extracellular matrix protein 1 measurement	ARNT PLEKHO1	1.68e-03	13	140	2	EFO_0008126
Disease	serum non-albumin protein measurement	KAT6A FCGR2C ARNT FCGR2A FCGR2B TP63 NFKB1	1.73e-03	361	140	7	EFO_0004568
Disease	phospholipids in very small VLDL measurement	HNF1A SIK3 ABCA6	1.84e-03	51	140	3	EFO_0022300
Disease	Orofacial cleft	SPRY2 ABCA4 TP63	1.84e-03	51	140	3	HP_0000202
Disease	complex trait	HNF1A GAPVD1 MAU2 SIK3 LEPR HHIP	1.91e-03	271	140	6	EFO_0010578
Disease	autoimmune thrombocytopenic purpura (is_implicated_in)	FCGR2A FCGR2B	2.25e-03	15	140	2	DOID:8924 (is_implicated_in)
Disease	Proteinuria	CRYL1 LRP2	2.25e-03	15	140	2	HP_0000093
Disease	cathepsin D measurement	GNPTAB MAU2	2.25e-03	15	140	2	EFO_0010611
Disease	Alzheimer disease	DVL2 ABCA7 SLC4A1AP NFIC PRRC2C PCDH11X MYO15A C17orf107	2.27e-03	485	140	8	MONDO_0004975
Disease	apolipoprotein A 1 measurement	PITPNM2 HNF1A SEMA7A ZMIZ1 SIK3 LEPR ABCA6 FCGR2B NFIC LPIN2 PLEKHO1	2.45e-03	848	140	11	EFO_0004614
Disease	level of triacylglycerol (56:6) in blood serum	MAU2 SIK3	2.57e-03	16	140	2	OBA_2020007
Disease	Malaria, susceptibility to	FCGR2A FCGR2B	2.57e-03	16	140	2	cv:C1970028
Disease	–	FCGR2A FCGR2B	2.57e-03	16	140	2	611162
Disease	Tourette syndrome, schizophrenia	PITPNM2 TBC1D5	3.25e-03	18	140	2	EFO_0004895, MONDO_0005090
Disease	esterified cholesterol measurement	HNF1A SIK3 LEPR ABCA6	3.29e-03	128	140	4	EFO_0008589
Disease	diet measurement, HOMA-B	MAGI1 NFAT5	3.63e-03	19	140	2	EFO_0004469, EFO_0008111
Disease	body surface area	FOXO1 BNC2 HIVEP1 KIZ ZMIZ1 HHIP PTPRG NFIC NPRL3	3.67e-03	643	140	9	EFO_0022196
Disease	Malaria	FCGR2A FCGR2B	4.02e-03	20	140	2	C0024530
Disease	corneal hysteresis	FOXO1 ABCA6	4.02e-03	20	140	2	EFO_0010066
Disease	selenium measurement, response to dietary selenium supplementation	TRIO LHX2	4.02e-03	20	140	2	EFO_0006331, EFO_0600021
Disease	diabetes mellitus	SPRY2 HNF1A ZMIZ1	4.18e-03	68	140	3	EFO_0000400
Disease	glycine measurement	KANSL1L ERBB4 CLSTN2 UNC80	4.19e-03	137	140	4	EFO_0009767
Disease	level of Phosphatidylinositol (18:0_18:2) in blood serum	HNF1A SIK3	4.42e-03	21	140	2	OBA_2045156
Disease	Manic Disorder	GRIN2A STARD9 PLEKHO1	4.72e-03	71	140	3	C0024713

Protein segments in the cluster

Peptide	Gene	Start	Entry
RSNEFIITQHPLPHT	PTPRG	1216	P23470
QPFSLHHPSRIQVSS	CCAR2	271	Q8N163
HRSSSSEQHVQQPPA	ARNT	736	P27540
HSTLPQHARTPLIAA	ERBB4	641	Q15303
HENRTFPSTQLPHQS	nan	281	Q9N2K0
LSALSHHSPRVPNSS	BIRC6	4251	Q9NR09
HLPAQARTSEPLHNV	BUB1	151	O43683
QQTESHDLPLHPRAA	ABCA4	2251	P78363
PSSIHHFENIPNSLA	BNC2	306	Q6ZN30
ASHILASHSPQRPLF	ARSI	216	Q5FYB1
APPAQNHDSSSFHSR	BAZ2B	141	Q9UIF8
HQPLPLASESQTHSF	BAZ2B	326	Q9UIF8
TSPNSDIRETHSHVP	GPR15	16	P49685
SHLDPTFSIPQANHS	FCGR2A	166	P12318
RSDPNFSIPQANHSH	FCGR2B	176	P31994
HTQHIRIESSPFPLS	ABCA6	991	Q8N139
HPEAFESSTPLHQAE	A2ML1	711	A8K2U0
EHFLTTDIPATLQHP	AADACL4	26	Q5VUY2
HPESRSSIQHSSVVP	CLSTN2	816	Q9H4D0
HLDSQTHRSPTQSQP	CCDC14	366	Q49A88
FHPNVSSSHENLEPE	DVL2	136	O14641
LEEPPVQHSSHRFSA	ABCA7	1306	Q8IZY2
HSAHPEPALNLTLAS	MTUS2	276	Q5JR59
LFQLTPHHTDPQTSR	RASA3	496	Q14644
PAHFQTDLLHPVSSD	TIPARP	156	Q7Z3E1
ASFLHIPHAEDIPNT	AOC2	676	O75106
QPSLRPHHDSSTFTL	PLOD3	661	O60568
VSSLHQAPPESSVSH	FAM47C	531	Q5HY64
VSSLHAEPPESRVSH	FAM47C	711	Q5HY64
VSESPFFSPIHLHSN	MISP	601	Q8IVT2
ARTHSTVPPRFLHSE	MUC16	9981	Q8WXI7
SSTIPRTIPNFSHHE	MUC16	10691	Q8WXI7
RTIPNFSHHESDATP	MUC16	10696	Q8WXI7
SFHSVLSLPSDVPLH	KANSL1L	631	A0AUZ9
HTASPSHSTQVLPEF	MAGI1	756	Q96QZ7
SSHLHSKITPPSQQR	LYSMD3	256	Q7Z3D4
PTFSSPAIESHIHRI	GNPTAB	381	Q3T906
LASRLNPPQIHHFSS	FAM149A	526	A5PLN7
HATSHPAVPITANSL	SPN	111	P16150
HLFSSHAPQAAPQRL	MYO15A	1741	Q9UKN7
HIASPPNFRLTHDIS	MAPK8IP1	26	Q9UQF2
PRQHSSSFTEPIQEA	GAB1	456	Q13480
PTFFRTHPSATLHNP	GABBR1	281	Q9UBS5
LANRSSVHSAPPLHE	AQP7B	326	A0A075B734
FPVLTHSTRNGLPDH	GAPVD1	1136	Q14C86
HPFTLTSAPHEDTLS	DUOX2	1316	Q9NRD8
RSDPNFSIPQANHSH	FCGR2C	176	P31995
SPPLHANTSLHVFVL	PCDHGC5	541	Q9Y5F6
THQALPSVSHPSDHI	PDE12	586	Q6L8Q7
LESQTHPTSPHSLQT	FAM205A	871	Q6ZU69
SPLAEQFSHQFPSHD	NPRL3	346	Q12980
QFSHQFPSHDLPSVL	NPRL3	351	Q12980
SPLATLLQHENPSHF	KCNJ13	251	O60928
NPSHFQSAVPHTTRT	MPP4	451	Q96JB8
QHLQPAHRLSASPTV	HNF1A	576	P20823
DQHPNIISPHLTFSE	LEPR	1041	P48357
LPGHHPSSEAQRFTD	LHX1	331	P48742
GHEPHSPSQTTLTNL	LHX2	391	P50458
NSLRSLHLDPENHSP	LRP2	2396	P98164
KHPEFAQLSNTIHTP	PRDM10	856	Q9NQV6
QIPFSRPESKHHASL	GNA15	101	P30679
PLSQASTQHHSPRVT	PCDH11X	1176	Q9BZA7
PSGPSHRHERTQSQA	PITPNM2	1301	Q9BZ72
FSIPDPHSHRQTAQS	KIZ	186	Q2M2Z5
LSHSPRHLTQQDPLS	MROH8	61	Q9H579
LSHPPSFTTVRVNTH	NSUN6	46	Q8TEA1
SLFHSPNPIVHSQTS	NFAT5	1091	O94916
PTSLTIHHPRESSNV	DSG1	906	Q02413
QSTHHSPRTPRSLDH	MED16	856	Q9Y2X0
FPQHHLRPLADSSTE	INTU	566	Q9ULD6
HHPILSPLESSFQLE	KICS2	176	Q96MD2
SHHSQISPILENPFS	SCYL3	446	Q8IZE3
SLNTHDVAAPLSPHS	POMT1	411	Q9Y6A1
ASEHNSPISSVQSHP	KAT6A	1476	Q92794
FEHQAPPRDHSLNAS	MALRD1	686	Q5VYJ5
ETHRHPSPQRNTTND	NLGN4Y	706	Q8NFZ3
QLHEFSSPSHLLRTP	TP63	606	Q9H3D4
LSRSPSPFTHTHLAQ	BRCA1	1186	P38398
LQDILVSASHSPDHP	BTBD18	426	B2RXH4
LPNQSFPHSVKTTTH	FOXO1	636	Q12778
LLNSTQSAPHHFPDS	COLCA2	6	A8K830
HFHSSTEVALQPPLL	C17orf107	16	Q6ZR85
RDSLAPLQAEHSQPH	COBL	576	O75128
LEPHSTLSPQEDHSN	CEP350	1126	Q5VT06
LTDSLQSPSAPHHAV	LYST	2571	Q99698
HPETAPTTVDRTHAL	CRYL1	161	Q9Y2S2
SSHSPHPLFASQQRD	EMX2	101	Q04743
EQHLDVSSTTPSPAH	FIGNL2	16	A6NMB9
DSLTDPSHINHPTNL	FRY	2026	Q5TBA9
PDRTPFHTSLHQGTS	DMTN	271	Q08495
EPLHLFLSSATPVHS	OLAH	121	Q9NV23
LERINPDHSFPVSSH	MAU2	441	Q9Y6X3
LLHESFPRPATSHSL	IFT140	706	Q96RY7
SHPFGVHNSRLSPDL	POM121L1P	11	Q3SYA9
NVHFLSSLLPAHRSP	TESMIN	121	Q9Y4I5
GLPRFHSVSTQSEPH	VARS2	21	Q5ST30
LPHNHTDLNSSTEEP	UTY	566	O14607
GSQPHSPRVHSLFTE	TEX14	566	Q8IWB6
LLQPTTNPHTSASHR	SMG5	591	Q9UPR3
NSPVTHVAANTLPHL	NBEA	2596	Q8NFP9
PHSSFKPDNHVRIDN	PRRC2C	1301	Q9Y520
HPHLFSDQSRGSPSS	SIK3	891	Q9Y2K2
TATTAQEPATSHPHR	SDC1	141	P18827
SQPRHLPDHTSEASF	SPATA31E1	326	Q6ZUB1
PSADTARSHILEQHP	SPINDOC	101	Q9BUA3
RAETHSSSTPVQHPI	WAC	236	Q9BTA9
SNGRSFLELHSPHSP	STARD9	3971	Q9P2P6
FSSSHLPQPSRHQEI	SWT1	741	Q5T5J6
QDSPRLSSFTQHHRP	NFIC	341	P08651
PDSHLRQTTPHSQYR	PLEKHO1	391	Q53GL0
RTPITLPQQHTHVFA	REELD1	201	A0A1B0GV85
SPHSQSLFHSPEREV	HHIP	116	Q96QV1
PPRLQHSQVHSSARA	SPRY2	91	O43597
DPQQPTFSLTAHLHQ	CIAO1	286	O76071
SPVRSFQPLASRHHS	CLASP2	541	O75122
QSPHQRQHASDALSP	TRAK2	71	O60296
TLSHSPLPAHLQQAF	UBN2	1316	Q6ZU65
HSHHTLVSDLPDPSN	UNC80	541	Q8N2C7
SHSSLHPVLLPSDVF	RNPC3	296	Q96LT9
SVQQDHLSRHPPETY	SPATA31A1	296	Q5TZJ5
NPHRTNSFSLSPLHS	REV1	291	Q9UBZ9
HTPQLHTPSSSQERE	SARG	226	Q9BW04
SVQRTHSLPVHSSPQ	SAMD4B	636	Q5PRF9
QDPHSSQAFHTPSSL	TONSL	671	Q96HA7
STPARHNSIHSPSFR	THSD1	446	Q9NS62
RPTLSATPNHVEHTL	TNS1	386	Q9HBL0
QTEPHTVLFHEPGSS	SEMA7A	71	O75326
SQESTLVHPATPNHL	SEMA5B	1066	Q9P283
LSPGNRHHPVFSSSD	PRAG1	866	Q86YV5
EHFPLTLESARPSHT	TRB	91	P0DTU4
DFHLNHQQPSPTSVL	ZNF839	661	A8K0R7
HPVTRSHFTQDLQPE	ZNF479	86	Q96JC4
NRRESSPPHSVHSFS	ZIM2	21	Q9NZV7
LRFILHHSDPASSPQ	TXNDC11	791	Q6PKC3
NPPAERHSSLHTSDV	ZNF350	436	Q9GZX5
AAELLQHPEHFVPSS	UNQ6494/PRO21346	126	Q6UXR6
FSPPSHHAQQLSVLA	ZNF827	156	Q17R98
PSRHSSLDFDHQEPF	TRMT9B	286	Q9P272
EHFPLTLESARPSHT	TRBV25-1	91	A0A075B6N4
SHVARLESSDLTPPH	PLEKHG2	1246	Q9H7P9
PTRTSAEAPSHHLQQ	TBC1D5	496	Q92609
TPSFESLSQKHPQHS	TEX15	331	Q9BXT5
HADNPSNTVTSVPTH	THAP10	156	Q9P2Z0
HFSVLSFTPRPQDHN	SIGLEC10	196	Q96LC7
FSHLPLHSQQQSRTP	HIVEP1	2381	P15822
HTHLPQTPETNFRDS	ZMYM4	211	Q5VZL5
SEPTALHSSEPQHSL	ZBTB26	206	Q9HCK0
RHHPPVLVSSAASSQ	TRIO	2346	O75962
HPHSDLTFNPSSALE	ZMIZ1	1001	Q9ULJ6
PPSHTSLNFHLIDFN	TMEM39B	111	Q9GZU3
REEPTTFHSRPASTH	MUC12	3966	Q9UKN1
SDHHPRTATITPSEN	LPIN2	281	Q92539
RPPTDLTHFKETQTH	SLC4A1AP	691	Q9BWU0
SLLPDHTSDNPFLHS	GRIN2A	1356	Q12879
HLDPSLTHTIFNPEV	NFKB1	16	P19838